Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis

Extent and Impact of Inadequate Disease Control in US Adults with a History of Moderate to Severe Atopic Dermatitis Following Introduction of New Treatments

(2021) Andreas Westh Vilsbøll et al.   Dermatology and Therapy

Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis

(2021) Thomas Bieber et al.   NEW ENGLAND JOURNAL OF MEDICINE

Upadacitinib plus topical corticosteroids in atopic dermatitis: week-52 AD Up study results

(2021) Jonathan I. Silverberg et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Atopic dermatitis: an expanding therapeutic pipeline for a complex disease

(2021) Thomas Bieber   NATURE REVIEWS DRUG DISCOVERY

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis

(2021) Andrew Blauvelt et al.   JAMA Dermatology

What are the best endpoints for Eczema Area and Severity Index and Scoring Atopic Dermatitis in clinical practice? A prospective observational study

(2020) J.I. Silverberg et al.   BRITISH JOURNAL OF DERMATOLOGY

European Task Force on Atopic Dermatitis (ETFAD): treatment targets and treatable traits in atopic dermatitis

(2020) J.P. Thyssen et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Tralokinumab plus topical corticosteroids for the treatment of moderate‐to‐severe atopic dermatitis: results from the double‐blind, randomized, multicentre, placebo‐controlled phase III ECZTRA 3 trial

(2020) J.I. Silverberg et al.   BRITISH JOURNAL OF DERMATOLOGY

Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)

(2020) A. Wollenberg et al.   BRITISH JOURNAL OF DERMATOLOGY

Atopic dermatitis is an IL-13 dominant disease with greater molecular heterogeneity compared to psoriasis

(2019) Lam C. Tsoi et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate‐to‐severe atopic dermatitis

(2019) G. Yosipovitch et al.   BRITISH JOURNAL OF DERMATOLOGY

Interleukin‐13: Targeting an underestimated cytokine in atopic dermatitis

(2019) Thomas Bieber   ALLERGY

Characterising Treatment‐related Patient Needs in Atopic Eczema: Insights for Personalised Goal Orientation

(2019) M. Augustin et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Effects of structured patient education in adults with atopic dermatitis: Multicenter randomized controlled trial

(2017) Annice Heratizadeh et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Structural Characterisation Reveals Mechanism of IL-13-Neutralising Monoclonal Antibody Tralokinumab as Inhibition of Binding to IL-13Rα1 and IL-13Rα2

(2017) B. Popovic et al.   JOURNAL OF MOLECULAR BIOLOGY

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

(2017) Andrew Blauvelt et al.   LANCET

Expert Perspectives on Management of Moderate-to-Severe Atopic Dermatitis: A Multidisciplinary Consensus Addressing Current and Emerging Therapies

(2017) Mark Boguniewicz et al.   Journal of Allergy and Clinical Immunology-In Practice

End points in dermatologic clinical trials: A review for clinicians

(2016) Erin X. Wei et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Determining the Minimal Clinically Important Difference and Responsiveness of the Dermatology Life Quality Index (DLQI): Further Data

(2015) M.K.A. Basra et al.   DERMATOLOGY